Key facts
- Notable investors include Lenovo Capital and Incubator Group, Furong Capital, Pudong Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Pudirui Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Pudirui Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pudirui Pharmaceutical
Developer of innovative drugs designed for major neurological diseases. The company offers drug research for Parkinson's disease, Huntington's chorea, and amyotrophic lateral sclerosis, thereby providing patients with more treatment options.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2023
- Website
- prodegrade.com/
- Ownership
- Privately Held (backing)
Pudirui Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pudirui Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pudirui Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.